Want to Join Our Team?
Learn about Blue Matter's innovative work experiences, enriching development opportunities, team-oriented "People First" culture, and a lot more.
Insights
Access our ever-expanding library of thought leadership resources for strategic leaders and professionals in biopharma. It’s full of useful content addressing industry challenges, best practices, therapeutic markets, innovative ideas, and forward-looking insights.
Featured Whitepaper
Key Success Factors to Building a Best Practice Medical Affairs Organization
Learn More >
Featured Whitepaper
Building Peak Performance Go-to-Market Operations: Capturing the Value of Medical Innovation in a Fast-Changing Landscape
Learn More >
Whitepaper
Customer Engagement in the Fast Lane: Accelerating Strategic Pull-Through With a Leaner Go-to-Market Formula
Presentation
Discerning the Proper Role of Artificial Intelligence (AI) in Strategic Decision Making
Blog
Case Study: Unlocking the Value of Patient Identification in Rare Disease Markets
Blog
Portfolio Asset Prioritization: Making Tough Calls (Part 2 in a Series on Portfolio Strategy)
Whitepaper
Blue Matter Deals Analysis: Reflection on Biopharma Deals in the First Half of 2025
Blog
Towards Skin Clearance in Dermatological Diseases: Updates from EADV 2025
Blog
Blue Matter Deals Analysis: Reflection on Biopharma Deals in the First Half of 2025
Presentation
Identifying Critical Paths to Brand Adoption Using a Behavioral-Science Based Approach (Intellus Institute 2025)
Blog
Portfolio Forecasting (Part 1): Finding the Optimum Approach to Portfolio Valuation
Whitepaper
How Science Can Drive Better Business Decisions in Biopharma
Blog
Highlights of EULAR 2025: Progress in Complex Rheumatological Diseases and Implications for the Future Landscape
Blog
Some Key Takeaways from ASCO 2025
Whitepaper
UK Biotech Club Recap (May 2025) – Navigating Transatlantic Headwinds: Assessing the Impact of U.S. Policy on the Growth of UK Biotech
Blog
Guidance for Evaluating MFN: Part 3 – Key Considerations for Deals
Blog
Autoimmune and Inflammatory Diseases in Women: Unmet Needs and Opportunities for Biopharma Companies
Blog
Guidance for Evaluating MFN: Part 2 – Impact on Pharma Channel Partner and Customer Business
